Karman Tandon1, David Tirschwell1, W T Longstreth1, Bryn Smith1, Nazem Akoum2. 1. From the Division of Cardiology (K.T., B.S., N.A.), Department of Medicine, Department of Neurology (D.T., W.T.L.), and Department of Epidemiology (W.T.L.), University of Washington, Seattle. 2. From the Division of Cardiology (K.T., B.S., N.A.), Department of Medicine, Department of Neurology (D.T., W.T.L.), and Department of Epidemiology (W.T.L.), University of Washington, Seattle. nakoum@cardiology.washington.edu.
Abstract
OBJECTIVE: To examine the hypothesis that atrial fibrosis and associated atrial cardiopathy may be in the causal pathway of cardioembolic stroke independently of atrial fibrillation (AF) by comparing atrial fibrosis burden between patients with embolic stroke of undetermined source (ESUS), patients with AF, and healthy controls. METHODS: We used late-gadolinium-enhancement MRI to compare atrial fibrosis in 10 patients with ESUS against 10 controls (no stroke, no AF) and 10 patients with AF. Fibrosis was compared between groups, controlling for stroke risk factors. RESULTS: Mean age was 51 ± 15 years, and 43% of participants were female. Patients with ESUS had more atrial fibrosis than controls (16.8 ± 5.7% vs 10.6 ± 5.7%, p = 0.019) and similar fibrosis compared to patients with AF (17.8 ± 4.8%, p = 0.65). Odds ratios of ESUS per quartile of fibrosis were 3.22 (95% CI [CI] 1.11-9.32, p = 0.031, unadjusted) and 3.17 (95% CI 1.05-9.52, p = 0.041, CHA2DVASc score adjusted). Patients with >12% fibrosis had a higher percentage of ESUS (77.8% vs 27.3%, p = 0.02), and patients with >20% fibrosis had the highest proportion of ESUS (4 of 5). CONCLUSIONS: Patients with ESUS exhibit similar atrial fibrosis compared to patients with AF and more fibrosis than healthy controls. Fibrosis is associated with ESUS after controlling for stroke risk factors, supporting the hypothesis that fibrosis is in the causal pathway of cardioembolic stroke independently of AF. Prospective studies are needed to assess the role of anticoagulation in primary and secondary stroke prevention in patients with high atrial fibrosis.
OBJECTIVE: To examine the hypothesis that atrial fibrosis and associated atrial cardiopathy may be in the causal pathway of cardioembolic stroke independently of atrial fibrillation (AF) by comparing atrial fibrosis burden between patients with embolic stroke of undetermined source (ESUS), patients with AF, and healthy controls. METHODS: We used late-gadolinium-enhancement MRI to compare atrial fibrosis in 10 patients with ESUS against 10 controls (no stroke, no AF) and 10 patients with AF. Fibrosis was compared between groups, controlling for stroke risk factors. RESULTS: Mean age was 51 ± 15 years, and 43% of participants were female. Patients with ESUS had more atrial fibrosis than controls (16.8 ± 5.7% vs 10.6 ± 5.7%, p = 0.019) and similar fibrosis compared to patients with AF (17.8 ± 4.8%, p = 0.65). Odds ratios of ESUS per quartile of fibrosis were 3.22 (95% CI [CI] 1.11-9.32, p = 0.031, unadjusted) and 3.17 (95% CI 1.05-9.52, p = 0.041, CHA2DVASc score adjusted). Patients with >12% fibrosis had a higher percentage of ESUS (77.8% vs 27.3%, p = 0.02), and patients with >20% fibrosis had the highest proportion of ESUS (4 of 5). CONCLUSIONS:Patients with ESUS exhibit similar atrial fibrosis compared to patients with AF and more fibrosis than healthy controls. Fibrosis is associated with ESUS after controlling for stroke risk factors, supporting the hypothesis that fibrosis is in the causal pathway of cardioembolic stroke independently of AF. Prospective studies are needed to assess the role of anticoagulation in primary and secondary stroke prevention in patients with high atrial fibrosis.
Authors: Ju Youn Kim; Kyung Geun Kim; Yunwon Tae; Mineok Chang; Seung-Jung Park; Kyoung-Min Park; Young Keun On; June Soo Kim; Yeha Lee; Sung-Won Jang Journal: Front Cardiovasc Med Date: 2022-07-06
Authors: Hooman Kamel; Kathleen Alwell; Brett M Kissela; Heidi J Sucharew; Daniel Woo; Matthew Flaherty; Simona Ferioli; Stacie L Demel; Charles J Moomaw; Kyle Walsh; Jason Mackey; De Los Rios La Rosa Felipe; Adam Jasne; Sabreena Slavin; Sharyl Martini; Opeolu Adeoye; Tehniyat Baig; Monica L Chen; Emily B Levitan; Elsayed Z Soliman; Dawn O Kleindorfer Journal: Neurology Date: 2020-11-25 Impact factor: 9.910
Authors: Björn Müller-Edenborn; Jan Minners; Cornelius Keyl; Martin Eichenlaub; Nikolaus Jander; Sherif Abdelrazek; Christoph Ahlgrim; Jürgen Allgeier; Heiko Lehrmann; Franz-Josef Neumann; Thomas Arentz; Amir Jadidi Journal: Sci Rep Date: 2022-01-12 Impact factor: 4.379